Thursday 20 December 2012
SLC45A3; solute carrier family 45, member 3; PCANAP2, PCANAP6, PCANAP8, "prostate cancer associated protein 2", "prostate cancer associated protein 6", "prostate cancer associated protein 8"; IPCA-2, IPCA-6, IPCA-8, prostein; 1q32.1
The majority of prostate cancer harbors recurrent gene fusions involving ETS transcription factors, most commonly ERG. The second most common 5’ fusion partner after TMPRSS2 is SLC45A3.
In cancer tissue, ERG protein expression showed a high rate of concordance with an underlying ERG rearrangement (91.5%).
SLC45A3 showed a weaker expression in cancer as compared to benign tissue, which was pronounced in cases with SLC45A3-ERG fusion. (#22821757#)
Importantly, SLC45A3 down regulation was significantly associated with shorter PSA-free survival times. (#22821757#)
In contrast, TMPRSS2 was neither differentially expressed nor did it show a correlation between protein expression and rearrangement status. (#22821757#)
The expression of SLC45A3 protein is down regulated through SLC45A3-ERG fusion in prostate cancer. (#22821757#)
Moreover, these cases may represent a distinct molecular subclass of ERG rearranged prostate cancer with distinct clinical features. (#22821757#)
ERG protein expression is predominantly found in prostate carcinomas with ERG gene rearrangement and does not occur in benign glands. (#22821757#)
Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G. Int J Cancer. 2012 Jul 23. PMID: #22821757#